长期使用骨骼肌松弛药治疗慢性疼痛:一项系统评价
该系统评价检索了截至2023年12月4日的多个数据库,纳入30项随机临床试验(1314例参与者)和14项队列研究(1168例参与者),评估骨骼肌松弛药(SMRs)用于慢性疼痛至少1个月的效果。研究以短期(4-6周)为主,涉及9种SMRs,最常见为巴氯芬(11项,25%)、替扎尼定(8项,18%)和环苯扎林(7项,16%)。证据显示SMRs对三叉神经痛、颈痛和痛性痉挛效果最强,对纤维肌痛、下背痛和其他综合征不优于安慰剂;最常见不良反应为镇静和口干。作者认为临床医生应警惕不良反应,若疼痛相关目标未达到可考虑减停药物。
要点
- 长期使用SMRs可能对痛性痉挛或抽搐及颈痛患者有益,对下背痛、纤维肌痛和头痛似乎无益。
- 纳入30项RCT(1314例)和14项队列研究(1168例),研究以短期(4-6周)为主。
- 涉及9种SMRs,最常见为巴氯芬(11项,25%)、替扎尼定(8项,18%)和环苯扎林(7项,16%)。
- 最常见不良反应为镇静和口干,临床医生应警惕。
- 作者建议若疼痛相关目标未达到,可考虑减停SMRs。
适用人群与场景
- 慢性疼痛患者,按慢性疼痛综合征分为下背痛、纤维肌痛、头痛、痛性痉挛或痉挛状态及其他综合征。
- 纳入评估至少1个月SMRs治疗的随机临床试验和队列研究,文章语言为英语、西班牙语或意大利语。
研究设计与关键结果
- 共纳入30项RCT(1314例参与者)和14项队列研究(1168例参与者),评估SMRs用于慢性疼痛。
- 研究以短期(4-6周)为主,涉及9种SMRs;巴氯芬11项(25%)、替扎尼定8项(18%)、环苯扎林7项(16%)。
- SMRs对三叉神经痛、颈痛和痛性痉挛的有效性证据最强;对纤维肌痛、下背痛和其他综合征不优于安慰剂。
- 最常见不良反应为镇静和口干。
- RCT偏倚风险为低至中等,队列研究质量尚可至良好。
证据类型、等级与局限
- 研究类型:系统评价,纳入随机临床试验和队列研究。
- RCT偏倚风险为低至中等,队列研究质量尚可至良好。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,长期使用SMRs可能对痛性痉挛或抽搐及颈痛患者有益;对下背痛、纤维肌痛和头痛似乎无益。
- 作者建议临床医生应警惕不良反应,若疼痛相关目标未达到可考虑减停药物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Stricter opioid prescribing guidelines have increased prescriptions of skeletal muscle relaxants (SMRs) for chronic pain, but the efficacy of long-term use of SMRs for chronic pain is unknown.
OBJECTIVE: To systematically review the effectiveness or efficacy of long-term use of SMRs for chronic pain.
EVIDENCE REVIEW: Two reviewers systematically searched Ovid MEDLINE, Embase (Ovid), Web of Science, CINAHL, and Cochrane through December 4, 2023. They included articles published in English, Spanish, or Italian. Only randomized clinical trials (RCTs) and cohort studies with comparator groups evaluating at least 1-month duration of SMRs for chronic pain were included. The reviewers dually reviewed data abstraction, risk-of-bias, and quality. They characterized studies by chronic pain syndrome: low back pain, fibromyalgia, headaches, painful cramps or spasticity, and other syndromes.
FINDINGS: A total of 30 RCTs with 1314 participants and 14 cohort studies with 1168 participants assessed SMRs for chronic pain. Studies were primarily short-term (4-6 weeks). Nine unique SMRs were represented by the studies identified. Eleven studies (25%) examined baclofen, 8 (18%) examined tizanidine, and 7 (16%) examined cyclobenzaprine. Evidence for effectiveness was strongest for SMRs used for trigeminal neuralgia, neck pain, and painful cramps; evidence suggested SMRs for fibromyalgia, low back pain, and other syndromes were not more beneficial than placebo. The most common adverse effects were sedation and dry mouth. RCTs had a low to moderate risk of bias, and the quality of cohort studies was fair to good.
CONCLUSIONS AND RELEVANCE: In this systematic review of long-term use of SMRs for chronic pain, findings suggest that their long-term use may benefit patients with painful spasms or cramps and neck pain; their long-term use for low back pain, fibromyalgia, and headaches did not appear to be beneficial. Clinicians should be vigilant for adverse effects and consider deprescribing if pain-related goals are not met.
参考来源
- Oldfield BJ, Gleeson B, Morford KL, et al. Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review. JAMA Netw Open. 2024. PMID: 39298168. doi:10.1001/jamanetworkopen.2024.34835
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。